Skip to content

A retrospective study of the Observations on the Effects of Low-Dose Esketamine for Postoperative Analgesia and Antidepressant Effects in Cesarean Section Patients

A retrospective study of the Observations on the Effects of Low-Dose Esketamine for Postoperative Analgesia and Antidepressant Effects in Cesarean Section Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090419
Enrollment
Unknown
Registered
2024-09-29
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum pain and depression

Interventions

Control Group:none
Esketamine Group I:none
Esketamine Group II:none

Sponsors

Jiangyin People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1)Age 18-40 years; (2)ASA Class II; (3)Pregnancy over 37 weeks; (4)Requires postoperative analgesic treatment; (5)No severe cardiovascular or cerebrovascular diseases; (6)Able to communicate well with the follow-up personnel; (7)Voluntarily participates in the study and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1) Persons with pregnancy-induced hypertension, thyroid dysfunction, preeclampsia and eclampsia, psychosis, inability to communicate pain response; (2) Abnormal increase in uterine activity, such as tetanic contractions, placental abruption, and umbilical cord prolapse; (3) Patients with contraindications for epidural catheterization such as spinal injury history or deformity; (4) People who are allergic to opioids or have a history of abuse of such drugs (5) Patients at serious risk of elevated blood pressure or intracranial pressure; (6) Patients with poorly controlled or untreated hypertension; (7) severe fetal abnormalities; (8) dangerous placenta previa; (9) Patients with labor analgesia.

Design outcomes

Primary

MeasureTime frame
EPDS scores ;nflammatory cytokine (IL-6), neurotransmitter (5-HT), and hormone (PRL) levels before and after 7 and 28 days postpartum;

Secondary

MeasureTime frame
VAS score;Maternal hospitalization days and satisfaction;

Countries

China

Contacts

Public ContactLiu Wanchao

Jiangyin People's Hospital

975886026@qq.com+86 183 6120 5651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026